NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.precisionbiosciences.comPrecision BioSciences, Inc. anticipates the completion of its Phase 1 clinical trial for PBGENE-HBV on December 1, 2026. This trial evaluates the safety and antiviral efficacy of PBGENE-HBV in adult patients suffering from chronic Hepatitis B, with an enrollment target of 45 participants. The trial, currently in the recruiting status since its start date of November 14, 2024, aims to gather crucial data regarding the drug's performance in this patient population. This development is significant for investors as it could lead to advancements in Hepatitis B treatments and impact Precision BioSciences' market position within the biotechnology sector.
Clinical Trial Completion